Luxembourg may be one of the smallest nations in the world, at just over 2,500 square kilometers and around 670,000 inhabitants, but it packs a punch in the global life sciences ecosystem. With world-class research institutes, startup accelerators, and the country’s growing digital prowess, Luxembourg is attracting global talent and putting digital healthtech solutions front and center.
So, how did the Grand Duchy establish and grow its thriving research and startup landscape, and what is the vision for the future?
In our overfed yet undernourished modern society, we must understand how the things we eat contribute to our gut microbiome and overall health. Analyzing how the friendly and not-so-friendly communities of microbes in our gut respond to our daily intake of food, additives, supplements, and pharmaceuticals will help companies formulate more nutritious products while providing us with crucial insights to help us all be healthier for longer.
Could we ever recreate the complexity of the human brain in the lab?
Over ten years ago, researchers aimed to do just that by developing a three-dimensional cell culture method to grow the first ever miniaturized versions of the human brain, so-called ‘brain organoids.’ Innovation in this field continues at a rapid pace, with researchers in Luxembourg and around the world refining methods to grow organoids that resemble specific brain regions. These advances can help us understand the effects of Parkinson’s disease on cells while driving the discovery of novel therapeutics beneficial to those in need.
At the heart of Europe, Benelux is like a drop of ink spreading its influence internationally; an in-depth study conducted by KBC Securities placed Belgium as Europe’s leading country for biotech in 2024. This year's edition of Knowledge for Growth, hosted by the life sciences cluster flanders.bio celebrating their 20th anniversary, highlighted the vibrant Flemish life sciences ecosystem. The event took place in Antwerp, Belgium on May 15th and 16th, where industry professionals, scientists, investors, policymakers, and more gathered to share their knowledge and insights and answer why the region of Flanders, and the Benelux overall, are doing so well in this vibrant landscape.
With its network of thematic SynBio Studios, investment company eureKARE is boosting the creation of new European start-ups in synthetic biology. Its first EU studio is located in Brussels and focuses on biomedical applications. Things are moving fast, and the studio has already welcomed two companies onboard.
Heusden-Zolder, Belgium, Schlieren, Zürich, Switzerland, and Luxembourg, Grand Duchy of Luxembourg, 12 October 2021 – Rejuvenate Biomed NV (‘Rejuvenate’), a biomedical company developing novel combination drugs for age-related diseases, today announces a EUR 15.7 million Series B round. The funding is being used to accelerate the clinical development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).
Luxembourg may be one of the smallest nations in the world, at just over 2,500 square kilometers and around 670,000 inhabitants, but it packs a punch in the global life sciences ecosystem. With world-class research institutes, startup accelerators, and the country’s growing digital prowess, Luxembourg is attracting global talent and putting digital healthtech solutions front and center.
So, how did the Grand Duchy establish and grow its thriving research and startup landscape, and what is the vision for the future?
In our overfed yet undernourished modern society, we must understand how the things we eat contribute to our gut microbiome and overall health. Analyzing how the friendly and not-so-friendly communities of microbes in our gut respond to our daily intake of food, additives, supplements, and pharmaceuticals will help companies formulate more nutritious products while providing us with crucial insights to help us all be healthier for longer.
Could we ever recreate the complexity of the human brain in the lab?
Over ten years ago, researchers aimed to do just that by developing a three-dimensional cell culture method to grow the first ever miniaturized versions of the human brain, so-called ‘brain organoids.’ Innovation in this field continues at a rapid pace, with researchers in Luxembourg and around the world refining methods to grow organoids that resemble specific brain regions. These advances can help us understand the effects of Parkinson’s disease on cells while driving the discovery of novel therapeutics beneficial to those in need.
At the heart of Europe, Benelux is like a drop of ink spreading its influence internationally; an in-depth study conducted by KBC Securities placed Belgium as Europe’s leading country for biotech in 2024. This year's edition of Knowledge for Growth, hosted by the life sciences cluster flanders.bio celebrating their 20th anniversary, highlighted the vibrant Flemish life sciences ecosystem. The event took place in Antwerp, Belgium on May 15th and 16th, where industry professionals, scientists, investors, policymakers, and more gathered to share their knowledge and insights and answer why the region of Flanders, and the Benelux overall, are doing so well in this vibrant landscape.
With its network of thematic SynBio Studios, investment company eureKARE is boosting the creation of new European start-ups in synthetic biology. Its first EU studio is located in Brussels and focuses on biomedical applications. Things are moving fast, and the studio has already welcomed two companies onboard.
Heusden-Zolder, Belgium, Schlieren, Zürich, Switzerland, and Luxembourg, Grand Duchy of Luxembourg, 12 October 2021 – Rejuvenate Biomed NV (‘Rejuvenate’), a biomedical company developing novel combination drugs for age-related diseases, today announces a EUR 15.7 million Series B round. The funding is being used to accelerate the clinical development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).